<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329365</url>
  </required_header>
  <id_info>
    <org_study_id>HSREB109061</org_study_id>
    <nct_id>NCT03329365</nct_id>
  </id_info>
  <brief_title>Paroxysmal Nocturnal Hemoglobinuria in ESUS &amp; ETUS</brief_title>
  <official_title>Paroxysmal Nocturnal Hemoglobinuria and Embolic Strokes of Undetermined Source (ESUS) and Transient Ischemic Attacks of Undetermined Source (ETUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder,&#xD;
      which can cause arterial or venous thrombosis. The frequency of PNH in young patients (&lt; 50&#xD;
      years old) with embolic stroke (ESUS), transient ischemic attack (ETUS) or superior sagittal&#xD;
      sinus cerebral venous thrombosis (SSS-CVTUS) of undetermined source, is currently unknown.&#xD;
      This study proposes to recruit ESUS, ETUS, SSS-CVTUS patients to determine the frequency of&#xD;
      PNH diagnosis confirmed by flow cytometry in these patient populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder&#xD;
      leading to red blood cells hemolysis and thrombosis. PNH has been reported to be the cause of&#xD;
      cerebral venous thrombosis and embolic ischemic strokes and is sometimes diagnosed after the&#xD;
      ischemic event. In young patients with embolic ischemic stroke of undetermined source (ESUS),&#xD;
      thrombophilia is usually investigated. However, access to PNH testing is limited. PNH is&#xD;
      rarely investigated in stroke patients and its contribution to the pathophysiology of ESUS is&#xD;
      unknown. The investigators hypothesize that this condition is underdiagnosed, resulting in&#xD;
      potential preventive opportunities being lost, since PNH can be successfully treated.&#xD;
&#xD;
      This observational study aims to determine the frequency of PNH among young (≤50 years old)&#xD;
      patients with recent ESUS or embolic transient ischemic attacks (TIA) of undetermined source&#xD;
      (ETUS) and patients with SSS-CVT of undetermined source (SSS-CVTUS).&#xD;
&#xD;
      Patients with ESUS or ETUS will be first screened for: (a) evidence of hemolysis based on&#xD;
      their plasma lactate dehydrogenase (LDH) levels, (b) unexplained anemia based on their&#xD;
      hemoglobin (Hb) levels, and (c) unexplained cytopenia (e.g., neutropenia and&#xD;
      thrombocytopenia). Flow cytometry analysis for PNH will be performed with blood samples&#xD;
      collected from subjects with abnormal level of plasma LDH (1.5X ULN) or unexplained anemia or&#xD;
      cytopenia.&#xD;
&#xD;
      Patients with SSS-CVTUS will undergo flow cytometry without prior screening.&#xD;
&#xD;
      In addition, plasma and DNA samples will be collected in an optional sub-study for future&#xD;
      analysis of DNA mutations related to specific PNH phenotypes in patients with stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of PNH in ESUS/ETUS/SSS-CVTUS</measure>
    <time_frame>At recruitment</time_frame>
    <description>Percentage of patients with flow-cytometry-confirmed PNH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of PNH in ESUS/ETUS</measure>
    <time_frame>At recruitment</time_frame>
    <description>Percentage of ESUS/ETUS patients with flow-cytometry-confirmed PNH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of PNH in SSS-CVT</measure>
    <time_frame>At recruitment</time_frame>
    <description>Percentage of SSS-CVTUS patients with flow-cytometry-confirmed PNH</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Embolic Stroke of Undetermined Source</condition>
  <condition>Transient Ischemic Attack</condition>
  <condition>Cerebral Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>ESUS/ETUS</arm_group_label>
    <description>Patients with embolic ischemic stroke or transient ischemic attack of undetermined source</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSS-CVTUS</arm_group_label>
    <description>Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ESUS, ETUS, or SSS-CVTUS attending the Urgent TIA and Stroke Prevention&#xD;
        Clinic or admitted to University or Victoria Hospital, in London, Ontario, Canada.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Participants with embolic ischemic stroke (ESUS), embolic transient ischemic attack&#xD;
             (ETUS) or cerebral venous thrombosis (CVTUS) of undetermined source.&#xD;
&#xD;
        For transient ischemic attack (TIA):&#xD;
&#xD;
        One of the following criteria needs to be fulfilled to be considered as embolic TIA:&#xD;
&#xD;
          -  Focal symptoms suggesting involvement of de cerebral cortex in the middle cerebral&#xD;
             artery (MCA) territory (e.g., aphasia, neglect, apraxia, dystextia, anosognosia,&#xD;
             isolated leg, arm or hand weakness). Some of these symptoms have been described as&#xD;
             associated with subcortical fibers connecting cortical areas as well but, despite&#xD;
             this, they are usually related to cortical localizations. Patients with hemianopia&#xD;
             will be included only if hemianopia is not the primary symptom or an isolated symptom.&#xD;
&#xD;
          -  Rapidly resolving hemispheric symptoms. This concept comprises two components: (a)&#xD;
             sudden onset hemispheric syndrome: sudden onset of symptoms and signs implicating&#xD;
             extensive ischemia in the internal carotid artery (ICA) or MCA territories, including&#xD;
             hemiparesis, hemianopia, conjugate eye deviation, other cortical signs, or altered&#xD;
             consciousness; and (b) spectacular shrinking deficit: improvement within 24 hours&#xD;
             (approximately).&#xD;
&#xD;
          -  Symptoms involving more than one vascular territory within a single hemisphere (e.g.&#xD;
             left sided weakness + left homonymous hemianopia) or both (e.g., left sided weakness&#xD;
             and aphasia in a right-handed patient).&#xD;
&#xD;
          -  Simultaneous embolization to other organs (e.g., bowel, spleen, liver, kidneys, toes).&#xD;
&#xD;
          -  Transient monocular blindness (amaurosis fugax) with no evidence of giant cell&#xD;
             arteritis (e.g., normal erythrocyte sedimentation rate).&#xD;
&#xD;
          -  No definite cortical symptoms but neuroimaging evidence of prior (chronic) typical&#xD;
             infarct (wedge shaped, involving the cerebral cortex).&#xD;
&#xD;
        All of the following criteria must be fulfilled to be considered as TIA of undetermined&#xD;
        source:&#xD;
&#xD;
          -  No neuroimaging evidence of an acute brain infarct within the brain region(s)&#xD;
             responsible for the presenting symptoms.&#xD;
&#xD;
          -  Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis&#xD;
             in arteries supplying the area of ischemia.&#xD;
&#xD;
          -  No major-risk cardioembolic source of embolism.&#xD;
&#xD;
          -  No other specific cause of stroke identified (e.g., arteritis, dissection, migraine,&#xD;
             vasospasm, or drug abuse).&#xD;
&#xD;
          -  No persistent neurological focal symptoms at the time of neurological examination. The&#xD;
             presence of persistent neurological focal symptoms in the absence of a visible brain&#xD;
             infarct on DWI MRI will be regarded as a &quot;clinically confirmed stroke with negative&#xD;
             DWI MRI&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
        For stroke patients:&#xD;
&#xD;
          -  Evidence of &gt;50% stenosis of the internal carotid artery (ICA) or MCA ipsilateral to&#xD;
             the qualifying ischemic stroke on neurovascular imaging studies.&#xD;
&#xD;
          -  Ischemic stroke involving deep structures and measuring &lt; 15 mm on diffusion-weighted&#xD;
             (DWI) magnetic resonance imaging (MRI). Cortical strokes measuring &lt;15 mm will qualify&#xD;
             to be included in the study.&#xD;
&#xD;
          -  Evidence of a cause explaining the stroke (e.g. hypercoagulable state or any other&#xD;
             major source of cardiac embolism).&#xD;
&#xD;
        For TIA patients:&#xD;
&#xD;
          -  Patients no fulfilling the criteria for ETUS.&#xD;
&#xD;
        For cerebral venous thrombosis patients:&#xD;
&#xD;
          -  Subjects without involvement of the superior sagittal sinus (SSS)&#xD;
&#xD;
          -  Subjects with an evident cause explaining the thrombosis (e.g., thrombophilia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano A Sposato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Center, Western University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justina Diaz Legaspe</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>35826</phone_ext>
    <email>Justina.Diazlegaspe@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justina Diaz Legaspe, PhD</last_name>
      <phone>519-663-3110</phone>
      <email>justina.diazlegaspe@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flow cytometry</keyword>
  <keyword>Lactate dehydrogenase (LDH) release</keyword>
  <keyword>Anemia</keyword>
  <keyword>Cytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Embolic Stroke</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

